BridgeBio Pharma Inc. has entered into a significant financial agreement involving the sale of royalty interests. On June 27, 2025, BridgeBio and its subsidiary Eidos Therapeutics, Inc. finalized a Royalty Interest Purchase and Sale Agreement with Acoramidis Royalty SPV, LP and LSI Financing Fund, LP. This agreement involves Eidos selling certain royalty payment rights from net sales of products containing acoramidis in the European Union and related territories. In exchange, the purchasers have agreed to pay Eidos $300 million in cash. The purchasers' rights are capped annually at 60% of royalty payments from Bayer and include an initial hard cap of 145% of the purchase price. This arrangement is secured by specific assets and includes standard representations, warranties, and indemnification obligations.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.